



Partnership Hub Snapshot

March 2016

In This Issue

[WIPO Re:Search Statistics](#)
[Cornerstones of Collaboration](#)
[New Member Announcement](#)
[Partnership Hub Central](#)
[Funding Announcement](#)
[Member Spotlight](#)
[Highlighted Contributions](#)
[WIPO Re:Search In the News](#)
[Upcoming Global Health Events](#)

Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

BVGH established the 100th WIPO Re:Search collaboration last month! This is an important milestone for WIPO Re:Search. It's only been four years since the Consortium was launched, but as evidenced by the number of collaborations – and more importantly the number of advancing collaborations – WIPO Re:Search is having an impact.

Seventy percent of WIPO Re:Search User and Provider Members have participated in a collaboration. If you have not yet been engaged in a WIPO Re:Search partnership, please reach out to [Ujwal Sheth](#) to schedule a call to discuss your research interests and needs. We look forward to identifying innovative projects that leverage your assets and expertise to advance neglected infectious disease product development.

I will be participating in the United Nations Secretary-General's High-Level Panel on Access to Medicines in London this week. The objective of the Panel's discussion is to propose incremental modifications to existing pharmaceutical innovation and access models. I look forward to seeing some of you in London.

I am pleased to welcome our newest Member, the **Research Institute for Tropical Medicine (RITM)**, to WIPO Re:Search.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH




WIPO Re:Search Statistics



To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).

Click [here](#) to view a complete list of WIPO Re:Search Members.



Cornerstones of Collaboration

Dr. David Griggs, Director of Cellular and Molecular Biology, and Dr. Marv Meyers, Director of Medicinal Chemistry, **Center for World Health & Medicine (CWHM)**, recently published the results of their WIPO Re:Search collaboration with **Pfizer** and **Sanofi**. Through this collaboration, David, Marv, and colleagues at Saint Louis University and **PATH** assessed Pfizer and Sanofi neutral endopeptidase inhibitors in a rat model of acute secretory diarrhea. Click [here](#) to read the paper.

New Member Announcement


We are pleased to announce that the **Research Institute for Tropical Medicine (RITM)** has joined WIPO Re:Search.



The Research Institute for Tropical Medicine, based in Manila, Philippines, was established in 1981 to plan and implement research programs for tropical infectious diseases. Research areas of interest at RITM include schistosomiasis vaccine development, lymphatic filariasis and leprosy diagnostic development, dengue fever clinical studies, and rabies vaccinology.

Partnership Hub Central

Ujwal Sheth, BVGH, gave a presentation on accelerating anthelmintic discovery through WIPO Re:Search at the Anthelmintics: From Discovery to Resistance II conference in San Diego.



Dr. Thavy Long, a postdoctoral fellow at the **University of California, San Diego (UCSD)**, presented the results of her WIPO Re:Search collaboration with **GlaxoSmithKline (GSK)**. These results were recently [published](#) in *PLoS NTDs*.

While in San Diego, Ujwal met with researchers at the **University of California, San Diego (UCSD)** including Dr. Jim McKerrow, Dean, and Dr. Conor Caffrey, Associate Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences. During the visit, Jim gave Ujwal a tour of the Center for Discovery and Innovation in Parasitic Diseases (CDIPD) parasitology and high-throughput screening (HTS) facilities.



Dr. Jim McKerrow at the CDIPD HTS facility

BVGH FundFinder Featured Funding Announcement

MMV 14th Call for Proposals

Medicines for Malaria Venture (MMV) has open calls for proposals in the first quarter of each year. This year MMV is currently welcoming research proposals in three areas that it has highlighted as necessary for the control and eradication of malaria. These key areas are: compounds addressing the key priorities of the malaria eradication agenda; asexual liver and blood stage antimalarial compounds; and novel approaches for antimalarial compound screens.

Funding amount: Not specified

Funder: Medicines for Malaria Venture (MMV)

Deadline: March 25th, 2016

Eligibility: Not specified

For more information about BVGH FundFinder, please email [Roopa Sriram](mailto:Roopa.Sriram@bvgh.org).



Member Spotlight

Oussama Ben Fadhel, Project Manager in Technology Transfer, **Institut Pasteur de Tunis**, was selected to participate in the **Association of University Technology Managers (AUTM)** 2016 Annual Meeting,

which was held last month in San Diego.

“I think it was one of the better meetings that I've had with these masses of professionals. I was able to exchange with different people with a broad range of expertise and experiences. Whether via social media or in person, building relationships is a long-term process. The AUTM meeting was an excellent opportunity to strengthen my network one person at a time.” - Oussama Ben Fadhel



Oussama Ben Fadhel (left) and Stephen Gardner, Chief Counsel, Commercial Law Development Program (CLDP) (right). CLDP sponsored Oussama's participation at the AUTM 2016 Annual Meeting.

Highlighted Contributions

Featured this month are two contributions submitted by the National Institutes of Health (NIH) to the [WIPO Re:Search Database](#).

Dimeric Naphthylisoquinoline Alkaloids and Synthesis Methods Thereof (ID: 628)

The present invention provides methods of preparing dimeric naphthylisoquinoline alkaloids. Two monomeric naphthylisoquinoline alkaloids can be coupled together to form homodimers or heterodimers. Monomers may possess a C-8' to C-5 naphthalene/isoquinoline linkage. The present invention also provides new, medically useful homodimeric and heterodimeric naphthylisoquinoline compounds and derivatives thereof.

Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof (#1) (ID: 746)

Leishmania parasites are transmitted to their vertebrate hosts by infected phlebotomine sand fly bites.

Sand fly saliva is known to enhance *Leishmania* infection, while immunity to the saliva protects against infection. This invention claims nine major salivary proteins from the sand fly vector of *L. major*, *Phlebotomus papatasi*, nucleic acids encoding the proteins, vaccines comprising the proteins and/or nucleic acids, and methods of producing an immune response to prevent leishmaniasis.

For more information or to discuss potential collaborations regarding this technology, please contact [Ujwal Sheth](#).

WIPO Re:Search In the News

Dr. Dennis Liotta, Executive Director, Emory Institute for Drug Development, **Emory University**, mentioned WIPO Re:Search during his presentation at TED^XPlaceDesNations: “Transforming Lives” event. Click [here](#) to watch his talk.



Dennis Liotta described a drug discoverer’s approach to neglected diseases

Upcoming Global Health Events

Dates	Event Name	Location	Web Link
Mar. 29-31	World Vaccine Congress 2016	Washington, DC	Website
May 1-5	Keystone Symposium: Positive-Strand RNA Viruses	Austin, TX	Website
May 22-26	Keystone Symposium: New Approaches to Vaccines for Human and Veterinary Tropical Diseases	Cape Town, South Africa	Website



*Known as EMD in the US and Canada | **Known as Merck in the US and Canada



Copyright © 2016 BVGH, All rights reserved.

Our mailing address is:
401 Terry Avenue N., Seattle, WA 98109

[unsubscribe from this list](#) [update subscription preferences](#)

